Contract facts
NONEMODELING ANTHRACYCLINE-TRIGGERED VASCULAR DYSFUNCTION is a federal NONE award for Nasa Ames Research Center held by Brigham & Womens Hospital Inc. Estimated value $2M ($2M obligated). Current period of performance ends Sep 26, 2026. Last award drew 9 bidders. Place of performance: BOSTON MA. Related solicitation NNH21ZDA015N.
MODELING ANTHRACYCLINE-TRIGGERED VASCULAR DYSFUNCTION
Recompete timing
PublicCurrent PoP ends Sep 26, 2026 (36 days remaining). Agencies typically plan 12–18 months ahead — at 1.2 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordBrigham & Womens Hospital Inc — $20.7M obligated across 79 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 80ARC022CA007?
80ARC022CA007 (Modeling anthracycline-triggered vascular) is a Nasa Ames Research Center award with a potential value of $2M, currently held by Brigham & Womens Hospital Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 80ARC022CA007?
Nasa Ames Research Center awarded 80ARC022CA007 to Brigham & Womens Hospital Inc (potential $2M).
Who is the incumbent on 80ARC022CA007?
Brigham & Womens Hospital Inc is the incumbent with $20.7M across 79 related awards in SCOUT’s public footprint. The current period of performance ends Sep 26, 2026.
When does Brigham & Womens Hospital Inc’s 80ARC022CA007 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 26, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.
